公开(公告)号：EP3922251A1

公开(公告)日：2021-12-15

申请号：EP20798403.0

申请日：2020-04-23

申请人： Industry-Academic Cooperation Foundation, Yonsei University ,  CURACLE Co., Ltd.

发明人： KWON, Young-Guen ,  ZHANG, Haiying ,  PARK, Songyi ,  NOH, Minyoung ,  KIM, Yeomyeong ,  KIM, Myung-Hwa ,  AHN, Koo Hyeon ,  PYO, Jung-In

IPC分类号： A61K31/56 ,  A61K31/704 ,  A61K45/06 ,  A61P35/00

摘要： The present invention relates to a cancer immunotherapy adjuvant, wherein the adjuvant, when administered in combination with a cancer immunotherapy agent, activates the function of immune factors without causing in vivo side effects, to exhibit the effect of enhancing the kit for anticancer effect of the cancer immunotherapy agent, and thus can be effectively used as a cancer immunotherapy adjuvant.

公开(公告)号：EP2495242B1

公开(公告)日：2016-05-04

申请号：EP10827132.1

申请日：2010-10-29

申请人： Industry-Academic Cooperation Foundation Yonsei University

发明人： KWON, Young-Guen ,  SUH, Young-Ger

IPC分类号： C07D309/02 ,  C07D309/04 ,  A61K31/35 ,  A61P9/00

CPC分类号： C07D309/12 ,  C07D239/34 ,  C07D303/22 ,  C07D309/10 ,  C07D309/30 ,  C07J9/00 ,  C07J9/005 ,  C07J17/00 ,  C07J17/005 ,  C07J31/006 ,  C07J41/0055 ,  C07J43/003

公开(公告)号：EP2495242A2

公开(公告)日：2012-09-05

申请号：EP10827132.1

申请日：2010-10-29

申请人： Industry-Academic Cooperation Foundation, Yonsei University ,  Handok Pharmaceuticals Co., Ltd.

发明人： KWON, Young-Guen ,  SUH, Young-Ger

IPC分类号： C07D309/02 ,  C07D309/04 ,  A61K31/35 ,  A61P9/00

CPC分类号： C07D309/12 ,  C07D239/34 ,  C07D303/22 ,  C07D309/10 ,  C07D309/30 ,  C07J9/00 ,  C07J9/005 ,  C07J17/00 ,  C07J17/005 ,  C07J31/006 ,  C07J41/0055 ,  C07J43/003

摘要： The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.

摘要翻译： 本公开涉及一种新型血管渗漏抑制剂。 本公开的新型血管渗漏抑制剂抑制血管内皮细胞的凋亡，抑制由VEGF诱导的肌动蛋白应力纤维的形成，增强皮层肌动蛋白环结构，并且改善血管细胞之间紧密连接（TJ）的稳定性， 从而抑制血管渗漏。 本公开的血管渗漏抑制剂不仅具有降低血管渗透性的作用，而且还具有恢复受损血管的完整性的作用。 因此，本公开的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。 由于本公开的血管渗漏抑制剂是由市售或容易合成的胆固醇合成的，因此其具有显着优越的商业合成可行性。